Assessing Exelixis (EXEL) Valuation After Recent Short Term Share Price Pressure [Yahoo! Finance]
Exelixis, Inc. (EXEL)
Last exelixis, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.exelixis.com/phoenix.zhtml?c=120923&p=irol-mediaresources
Company Research
Source: Yahoo! Finance
Exelixis at a glance: recent returns and business snapshot Exelixis (EXEL) has drawn investor attention after a period where the stock posted a 0.2% move over the past day and a 2.3% decline across the past week. Over the past month, the share price return sits at 6.1%, with about 1% over the past 3 months and 1.8% year to date. The 1 year total return stands at 22.6%, while the 3 year and 5 year total returns are reported at roughly 13x and 8x the starting level respectively. The company, valued at about US$11.5b, focuses on oncology therapies, with revenue of US$2,320.126m and net income of US$782.57m. These figures correspond to annual revenue growth of 8.3% and net income growth of 12.2%. See our latest analysis for Exelixis. At a share price of US$44.38, Exelixis has experienced short term pressure, with a decline in its 7 day share price return, alongside a strong backdrop of longer term total shareholder returns over 1, 3 and 5 years. Recent moves suggest investors a
Show less
Read more
Impact Snapshot
Event Time:
EXEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXEL alerts
High impacting Exelixis, Inc. news events
Weekly update
A roundup of the hottest topics
EXEL
News
- Exelixis: The Double Backbone Potential Of CABOMETYX And Zanzalintinib [Seeking Alpha]Seeking Alpha
- Exelixis: Stable Demand And High Margins With Undervalued Shares [Seeking Alpha]Seeking Alpha
- RBC Capital Lowers Exelixis (EXEL) Price Target to $43 [Yahoo! Finance]Yahoo! Finance
- Exelixis (EXEL) was upgraded by Truist Financial Corporation to "strong-buy".MarketBeat
- Exelixis (EXEL) Valuation After Earnings Beat FDA Progress And Cabometyx Label Expansion [Yahoo! Finance]Yahoo! Finance
EXEL
Earnings
- 2/10/26 - Beat
EXEL
Sec Filings
- 4/17/26 - Form DEFA14A
- 4/15/26 - Form DEFA14A
- 4/15/26 - Form DEF
- EXEL's page on the SEC website